Display Settings:

Format

Send to:

Choose Destination
Gynecol Obstet Fertil. 2007 Jun;35(6):556-60. Epub 2007 Jun 1.

[Fetal toxicity of angiotensin-II-receptor inhibitors. Case report].

[Article in French]

Author information

  • 1Service de Gynécologie-Obstétrique, Maternité Aline-de-Crépy, Hôpital Bichat-Claude-Bernard, APHP, Université Paris-VII, 75018 Paris, France.

Abstract

The fetal toxicity of angiotensin-converting enzyme inhibitors (ACEI) is now well known. Sartans which are angiotensin II inhibitors, are supposed to have the same side effects on the fetus as ACEI because of their similar mechanism of action. This is supported by experimental and clinical data. Clinical presentation of fetal exposition to sartans varies from transient oligamnios to permanent renal failure, potentially complicated by Potter syndrome. According to previously reported cases, we report a case of transitory fetal oliguria secondary to the exposure to an angiotensin-II-receptor inhibitor (valsartan) between 19 and 21 weeks' gestation. We discuss the management of pregnancies exposed to angiotensin II inhibitors.

PMID:
17544313
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk